Table of Contents Author Guidelines Submit a Manuscript
Retracted

Cardiology Research and Practice has retracted this article. The article was found to contain a substantial amount of material from previously published articles (85% of the text), mostly without citation, including the following sources:(i)M.-A. Cornier, Dabelea D., Hernandez T. L. et al., “The metabolic syndrome,” Endocrine Reviews, vol. 29, no. 7, pp. 777–822, 2008, https://doi.org/10.1210/er.2008-0024 (not cited) [2], mainly in section 5, Pathophysiology, and section 6, Treatment.(ii)C. Peters, “Metabolic syndrome-a literature review,” Master of Nursing Thesis, University of Arizona, 2007. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.503.728&rep=rep1&type=pdf (not cited) [3], mainly in section 5, Pathophysiology, and section 6, Treatment.(iii)S. M. Grundy, Cleeman J. I., Daniels S. R. et al., “Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement,” Circulation, vol. 112, pp. 2735–2752, 2005, https://doi.org/10.1161/circulationaha.105.169404, http://circ.ahajournals.org/content/112/17/2735.full (cited as reference 20) [4], mainly in section 5, Pathophysiology, and section 6, Treatment.(iv)P. C. Deedwania, R. Gupta, “Management issues in the metabolic syndrome,” Journal of the Association of Physicians of India, vol. 54, 2006, http://www.japi.org/october2006/R-797.pdf (not cited) [5], mainly in section 6, Treatment.(v)P. L. Huang, “A comprehensive definition for metabolic syndrome,” Disease Models & Mechanisms, vol. 2, no. 5-6, pp. 231–237, 2009, doi: https://doi.org/10.1242/dmm.001180, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675814/ (not cited) [6], mainly in section 5, Pathophysiology.

This was raised to our attention by the publisher of Cornier et al. Hindawi regrets that this was not identified before publication. The authors said that their aim was to write a comprehensive review extracted from previously published studies on metabolic syndrome and their components, and they apologize for unintentionally not citing most of the sources, but disagree with retraction.

View the full Retraction here.

References

  1. J. Kaur, “A comprehensive review on metabolic syndrome,” Cardiology Research and Practice, vol. 2014, Article ID 943162, 21 pages, 2014.
  2. M.-A. Cornier, D. Dabelea, T. L. Hernandez et al., “The metabolic syndrome,” Endocrine Reviews, vol. 29, no. 7, pp. 777–822, 2008.
  3. C. Peters, “Metabolic syndrome-a literature review,” Master of Nursing Thesis, University of Arizona, Tucson, AZ, USA, 2007, http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.503.728&rep=rep1&type=pdf.
  4. S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005, http://circ.ahajournals.org/content/112/17/2735.full.
  5. P. C. Deedwania and R. Gupta, “Management issues in the metabolic syndrome,” Journal of the Association of Physicians of India, vol. 54, pp. 797–810, 2006, http://www.japi.org/october2006/R-797.pdf.
  6. P. L. Huang, “A comprehensive definition for metabolic syndrome,” Disease Models & Mechanisms, vol. 2, no. 5-6, pp. 231–237, 2009, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675814/.
Cardiology Research and Practice
Volume 2014, Article ID 943162, 21 pages
http://dx.doi.org/10.1155/2014/943162
Review Article

A Comprehensive Review on Metabolic Syndrome

Ex-Servicemen Contributory Health Scheme (ECHS) Polyclinic, Sultanpur Lodhi, Kapurthala District 144626, India

Received 20 November 2013; Accepted 19 January 2014; Published 11 March 2014

Academic Editor: Paul Holvoet

Copyright © 2014 Jaspinder Kaur. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. K. G. M. M. Alberti and P. Zimmet, “The metabolic syndrome—a new worldwide definition,” The Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. K. Olijhoek, Y. Van Der Graaf, J.-D. Banga, A. Algra, T. J. Rabelink, and F. L. J. Visseren, “The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm,” European Heart Journal, vol. 25, no. 4, pp. 342–348, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Grundy, “Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds,” Journal of the American College of Cardiology, vol. 47, no. 6, pp. 1093–1100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. K. G. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1998. View at Google Scholar
  6. B. Balkau and M. A. Charles, “Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR),” Diabetic Medicine, vol. 16, no. 5, pp. 442–443, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar · View at Scopus
  8. D. Einhorn, G. M. Reaven, R. H. Cobin et al., “American College of Endocrinology position statement on the insulin resistance syndrome,” Endocrine Practice, vol. 9, no. 3, pp. 237–252, 2003. View at Google Scholar · View at Scopus
  9. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome, http://www.idf.org/metabolic-syndrome.
  10. J. E. Shaw and K. G. M. M. Alberti, “Point: impaired fasting glucose: the case for the new American Diabetes Association criterion,” Diabetes Care, vol. 29, no. 5, pp. 1170–1172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Shaw and D. J. Chisholm, “Epidemiology and prevention of type 2 diabetes and the metabolic syndrome,” Medical Journal of Australia, vol. 179, no. 7, pp. 379–383, 2003. View at Google Scholar · View at Scopus
  12. E. Kylin, “Studien ueber das Hypertonie-Hyperglyca “mie- Hyperurika” miesyndrom,” Zentralblatt fuer Innere Medizin, vol. 44, pp. 105–127, 1923. View at Google Scholar
  13. J. Vague, “Sexual differentiation. A factor affecting the forms of obesity,” Presse Medicale, vol. 30, pp. S39–S40, 1947. View at Google Scholar
  14. P. Avogaro and G. Crepaldi, “Essential hyperlipidemia, obesity and diabetes,” Diabetologia, vol. 1, p. 137, 1965. View at Google Scholar
  15. G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988. View at Google Scholar · View at Scopus
  16. N. M. Kaplan, “The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension,” Archives of Internal Medicine, vol. 149, no. 7, pp. 1514–1520, 1989. View at Google Scholar · View at Scopus
  17. S. M. Haffner, R. A. Valdez, H. P. Hazuda, B. D. Mitchell, P. A. Morales, and M. P. Stern, “Prospective analysis of the insulin-resistance syndrome (Syndrome X),” Diabetes, vol. 41, no. 6, pp. 715–722, 1992. View at Google Scholar · View at Scopus
  18. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. E. S. Ford, “Prevalence of the metabolic syndrome in US populations,” Endocrinology and Metabolism Clinics of North America, vol. 33, no. 2, pp. 333–350, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. P. W. F. Wilson, R. B. D'Agostino, H. Parise, L. Sullivan, and J. B. Meigs, “Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus,” Circulation, vol. 112, no. 20, pp. 3066–3072, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Ritchie and J. M. C. Connell, “The link between abdominal obesity, metabolic syndrome and cardiovascular disease,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 17, no. 4, pp. 319–326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Desroches and B. Lamarche, “The evolving definitions and increasing prevalence of the metabolic syndrome,” Applied Physiology, Nutrition and Metabolism, vol. 32, no. 1, pp. 23–32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. D. Kolovou, K. K. Anagnostopoulou, K. D. Salpea, and D. P. Mikhailidis, “The prevalence of metabolic syndrome in various populations,” The American Journal of the Medical Sciences, vol. 333, no. 6, pp. 362–371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. J. Cameron, J. E. Shaw, and P. Z. Zimmet, “The metabolic syndrome: prevalence in worldwide populations,” Endocrinology and Metabolism Clinics of North America, vol. 33, no. 2, pp. 351–375, 2004. View at Publisher · View at Google Scholar
  26. Y.-W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon, and S. B. Heymsfield, “The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994,” Archives of Internal Medicine, vol. 163, no. 4, pp. 427–436, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey,” Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002. View at Google Scholar · View at Scopus
  28. A. Ponholzer, C. Temml, M. Rauchenwald, M. Marszalek, and S. Madersbacher, “Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?” International Journal of Impotence Research, vol. 20, no. 1, pp. 100–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. P. W. F. Wilson, W. B. Kannel, H. Silbershatz, and R. B. D'Agostino, “Clustering of metabolic factors and coronary heart disease,” Archives of Internal Medicine, vol. 159, no. 10, pp. 1104–1109, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Palaniappan, M. R. Carnethon, Y. Wang et al., “Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study,” Diabetes Care, vol. 27, no. 3, pp. 788–793, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. P. Reilly and D. J. Rader, “The metabolic syndrome: more than the sum of its parts?” Circulation, vol. 108, no. 13, pp. 1546–1551, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. E. A. Andreadis, G. I. Tsourous, C. K. Tzavara et al., “Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population,” The American Journal of Hypertension, vol. 20, no. 5, pp. 558–564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Halberg, I. Wernstedt-Asterholm, and P. E. Scherer, “The adipocyte as an endocrine cell,” Endocrinology and Metabolism Clinics of North America, vol. 37, no. 3, pp. 753–768, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Cinti, G. Mitchell, G. Barbatelli et al., “Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans,” Journal of Lipid Research, vol. 46, no. 11, pp. 2347–2355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. D. C. W. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma, “Adipokines: molecular links between obesity and atheroslcerosis,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 288, no. 5, pp. H2031–H2041, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Trayhurn and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” British Journal of Nutrition, vol. 92, no. 3, pp. 347–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. U. Saleem, M. Khaleghi, N. G. Morgenthaler et al., “Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2558–2564, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Tsimikas, J. Willeit, M. Knoflach et al., “Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study,” European Heart Journal, vol. 30, no. 1, pp. 107–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Jacobs, M. M. J. Van Greevenbroek, C. J. H. Van Der Kallen et al., “Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study,” European Journal of Clinical Investigation, vol. 39, no. 6, pp. 437–444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. Miles and M. D. Jensen, “Counterpoint: visceral adiposity is not causally related to insulin resistance,” Diabetes Care, vol. 28, no. 9, pp. 2326–2328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Boden, B. Lebed, M. Schatz, C. Homko, and S. Lemieux, “Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects,” Diabetes, vol. 50, no. 7, pp. 1612–1617, 2001. View at Google Scholar · View at Scopus
  42. S. E. Kahn, R. L. Prigeon, R. S. Schwartz et al., “Obesity, body fat distribution, insulin sensitivity and islet β-cell function as explanations for metabolic diversity,” Journal of Nutrition, vol. 131, no. 2, pp. 354S–360S, 2001. View at Google Scholar · View at Scopus
  43. A. M. Xydakis, C. C. Case, P. H. Jones et al., “Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight lose through caloric restriction,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2697–2703, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman, “IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance,” Science, vol. 271, no. 5249, pp. 665–668, 1996. View at Google Scholar · View at Scopus
  45. R. M. Krauss, “Lipids and lipoproteins in patients with type 2 diabetes,” Diabetes Care, vol. 27, no. 6, pp. 1496–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Soto González, D. Bellido Guerrero, M. Buño Soto, S. Pértega Díaz, M. Martinez-Olmos, and O. Vidal, “Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin,” European Journal of Clinical Nutrition, vol. 60, no. 6, pp. 802–809, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Deepa, K. Velmurugan, K. Arvind et al., “Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES),” Metabolism, vol. 55, no. 9, pp. 1232–1238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Guldiken, M. Demir, E. Arikan et al., “The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein,” Thrombosis Research, vol. 119, no. 1, pp. 79–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. T. McLaughlin, F. Abbasi, C. Lamendola et al., “Differentiation between obesity and insulin resistance in the association with C-reactive protein,” Circulation, vol. 106, no. 23, pp. 2908–2912, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, “C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women,” Circulation, vol. 107, no. 3, pp. 391–397, 2003. View at Google Scholar · View at Scopus
  51. M. B. Clearfield, “C-reactive protein: a new risk assessment tool for cardiovascular disease,” Journal of the American Osteopathic Association, vol. 105, no. 9, pp. 409–416, 2005. View at Google Scholar · View at Scopus
  52. B. K. Pedersen, A. Steensberg, C. Fischer et al., “Searching for the exercise factor: is IL-6 a candidate?” Journal of Muscle Research and Cell Motility, vol. 24, no. 2-3, pp. 113–119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Stenlöf, I. Wernstedt, T. Fjällman, V. Wallenius, K. Wallenius, and J.-O. Jansson, “Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 9, pp. 4379–4383, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Diamant, H. J. Lamb, M. A. Van De Ree et al., “The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1495–1501, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001. View at Google Scholar · View at Scopus
  56. G. Zuliani, S. Volpato, A. Blè et al., “High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study,” Atherosclerosis, vol. 192, no. 2, pp. 384–390, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. M.-C. Alessi and I. Juhan-Vague, “PAI-1 and the metabolic syndrome: links, causes, and consequences,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2200–2207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Cigolini, G. Targher, I. A. B. Andreis, M. Tonoli, G. Agostino, and G. De Sandre, “Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 3, pp. 368–374, 1996. View at Google Scholar · View at Scopus
  59. M. C. Alessi and I. Juhan-Vague, “Contribution of PAI-1 in cardiovascular pathology,” Archives des Maladies du Coeur et des Vaisseaux, vol. 97, no. 6, pp. 673–678, 2004. View at Google Scholar · View at Scopus
  60. H. P. Kohler and P. J. Grant, “Plasminogen-activator inhibitor type 1 and coronary artery disease,” The New England Journal of Medicine, vol. 342, no. 24, pp. 1792–1801, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Liu and F. Liu, “Transcriptional and post-translational regulation of adiponectin,” Biochemical Journal, vol. 425, no. 1, pp. 41–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Matsuzawa, T. Funahashi, S. Kihara, and I. Shimomura, “Adiponectin and metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 1, pp. 29–33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Kazumi, A. Kawaguchi, K. Sakai, T. Hirano, and G. Yoshino, “Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure,” Diabetes Care, vol. 25, no. 6, pp. 971–976, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Pischon, C. J. Girman, G. S. Hotamisligil, N. Rifai, F. B. Hu, and E. B. Rimm, “Plasma adiponectin levels and risk of myocardial infarction in men,” Journal of the American Medical Association, vol. 291, no. 14, pp. 1730–1737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Fumeron, R. Aubert, A. Siddiq et al., “Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study,” Diabetes, vol. 53, no. 4, pp. 1150–1157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. H.-S. Lee, M. Lee, and H. Joung, “Adiponectin represents an independent risk factor for hypertension in middle aged Korean women,” Asia Pacific Journal of Clinical Nutrition, vol. 16, no. 1, pp. 10–15, 2007. View at Google Scholar · View at Scopus
  67. N. Maeda, M. Takahashi, T. Funahashi et al., “PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein,” Diabetes, vol. 50, no. 9, pp. 2094–2099, 2001. View at Google Scholar · View at Scopus
  68. M. Fasshauer, S. Kralisch, M. Klier et al., “Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 301, no. 4, pp. 1045–1050, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Engeli, M. Feldpausch, K. Gorzelniak et al., “Association between adiponectin and mediators of inflammation in obese women,” Diabetes, vol. 52, no. 4, pp. 942–947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. N. Ouchi, S. Kihara, Y. Arita et al., “Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway,” Circulation, vol. 102, no. 11, pp. 1296–1301, 2000. View at Google Scholar · View at Scopus
  71. L. Hutley and J. B. Prins, “Fat as an endocrine organ: relationship to the metabolic syndrome,” The American Journal of the Medical Sciences, vol. 330, no. 6, pp. 280–289, 2005. View at Google Scholar · View at Scopus
  72. M. Carlyle, O. B. Jones, J. J. Kuo, and J. E. Hall, “Chronic cardiovascular and renal actions of leptin: role of adrenergic activity,” Hypertension, vol. 39, no. 2, pp. 496–501, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Eikelis, M. Schlaich, A. Aggarwal, D. Kaye, and M. Esler, “Interactions between leptin and the human sympathetic nervous system,” Hypertension, vol. 41, no. 5, pp. 1072–1079, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. A. J. Marsh, M. A. P. Fontes, S. Killinger, D. B. Pawlak, J. W. Polson, and R. A. L. Dampney, “Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus,” Hypertension, vol. 42, no. 4, pp. 488–493, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Shirasaka, M. Takasaki, and H. Kannan, “Cardiovascular effects of leptin and orexins,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 284, no. 3, pp. R639–R651, 2003. View at Google Scholar · View at Scopus
  76. R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” The New England Journal of Medicine, vol. 334, no. 5, pp. 292–295, 1996. View at Publisher · View at Google Scholar · View at Scopus
  77. D. M. Bravata, C. K. Wells, J. Concato, W. N. Kernan, L. M. Brass, and B. I. Gulanski, “Two measures of insulin sensitivity provided similar information in a U.S. population,” Journal of Clinical Epidemiology, vol. 57, no. 11, pp. 1214–1217, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. D. G. Carey, A. B. Jenkins, L. V. Campbell, J. Freund, and D. J. Chisholm, “Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM,” Diabetes, vol. 45, no. 5, pp. 633–638, 1996. View at Google Scholar · View at Scopus
  79. E. J. Mayer-Davis, R. D'Agostino Jr., A. J. Karter et al., “Intensity and amount of physical activity in relation to insulin sensitivity the Insulin Resistance Atherosclerosis Study,” Journal of the American Medical Association, vol. 279, no. 9, pp. 669–674, 1998. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Vessby, M. Uusitupa, K. Hermansen et al., “Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study,” Diabetologia, vol. 44, no. 3, pp. 312–319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Gill, M. Mugo, A. Whaley-Connell, C. Stump, and J. R. Sowers, “The key role of insulin resistance in the cardiometabolic syndrome,” The American Journal of the Medical Sciences, vol. 330, no. 6, pp. 290–294, 2005. View at Google Scholar · View at Scopus
  82. K. F. Petersen and G. I. Shulman, “Etiology of insulin resistance,” The American Journal of Medicine, vol. 119, no. 5, pp. S10–S16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. M. D. Jensen, M. W. Haymond, R. A. Rizza, P. E. Cryer, and J. M. Miles, “Influence of body fat distribution on free fatty acid metabolism in obesity,” Journal of Clinical Investigation, vol. 83, no. 4, pp. 1168–1173, 1989. View at Google Scholar · View at Scopus
  84. G. F. Lewis and G. Steiner, “Acute effects of insulin in the control of VLDL production in humans: implications for the insulin-resistant state,” Diabetes Care, vol. 19, no. 4, pp. 390–393, 1996. View at Google Scholar · View at Scopus
  85. H. N. Ginsberg, Y.-L. Zhang, and A. Hernandez-Ono, “Regulation of plasma triglycerides in insulin resistance and diabetes,” Archives of Medical Research, vol. 36, no. 3, pp. 232–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Ferrannini and A. Natali, “Essential hypertension, metabolic disorders, and insulin resistance,” The American Heart Journal, vol. 121, no. 4, pp. 1274–1282, 1991. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Malhotra, B. P. S. Kang, S. Cheung, D. Opawumi, and L. G. Meggs, “Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I,” Diabetes, vol. 50, no. 8, pp. 1918–1926, 2001. View at Google Scholar · View at Scopus
  88. S. A. Morse, R. Zhang, V. Thakur, and E. Reisin, “Hypertension and the metabolic syndrome,” The American Journal of the Medical Sciences, vol. 330, no. 6, pp. 303–310, 2005. View at Google Scholar · View at Scopus
  89. A. M. Briones, A. N. D. Cat, G. E. Callera et al., “Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction,” Hypertension, vol. 59, no. 5, pp. 1069–1078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. J. M. Ordovas, “Genetic links between diabetes mellitus and coronary atherosclerosis,” Current Atherosclerosis Reports, vol. 9, no. 3, pp. 204–210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. G. Perseghin, S. Ghosh, K. Gerow, and G. I. Shulman, “Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study,” Diabetes, vol. 46, no. 6, pp. 1001–1009, 1997. View at Google Scholar · View at Scopus
  92. N. Abate, M. Chandalia, P. G. Snell, and S. M. Grundy, “Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2750–2755, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. L. J. Martin, K. E. North, T. Dyer, J. Blangero, A. G. Comuzzie, and J. Williams, “Phenotypic, genetic, and genome-wide structure in the metabolic syndrome,” BMC Genetics, vol. 4, supplement 1, article S95, 2003. View at Publisher · View at Google Scholar
  94. M. Laakso, “Gene variants, insulin resistance, and dyslipidaemia,” Current Opinion in Lipidology, vol. 15, no. 2, pp. 115–120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Poulsen, K. Levin, I. Petersen, K. Christensen, H. Beck-Nielsen, and A. Vaag, “Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins,” Diabetes, vol. 54, no. 1, pp. 275–283, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. J. V. Neel, “Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”?” The American Journal of Human Genetics, vol. 14, pp. 353–362, 1962. View at Google Scholar · View at Scopus
  97. C. N. Hales and D. J. P. Barker, “Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis,” Diabetologia, vol. 35, no. 7, pp. 595–601, 1992. View at Publisher · View at Google Scholar · View at Scopus
  98. C. N. Hales, M. Desai, and S. E. Ozanne, “The thrifty phenotype hypothesis: how does it look after 5 years?” Diabetic Medicine, vol. 14, no. 3, pp. 189–195, 1997. View at Google Scholar
  99. F. Locatelli, P. Pozzoni, and L. Del Vecchio, “Renal manifestations in the metabolic syndrome,” Journal of the American Society of Nephrology, vol. 17, no. 4, supplement 2, pp. S81–S85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. K. D. Bruce and C. D. Byrne, “The metabolic syndrome: common origins of a multifactorial disorder,” Postgraduate Medical Journal, vol. 85, no. 1009, pp. 614–621, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Padhi and Garima, “Metabolic syndrome and skin: psoriasis and beyond,” Indian Journal of Dermatology, vol. 58, no. 3, pp. 299–305, 2013. View at Publisher · View at Google Scholar
  102. R. Chopra, A. Chander, and J. J. Jacob, “Ocular associations of metabolic syndrome,” Indian Journal of Endocrinology and Metabolism, vol. 16, supplement 1, pp. S6–S11, 2012. View at Google Scholar
  103. J. C. M. Lam and S. M. I. Mary, “Sleep & the metabolic syndrome,” Indian Journal of Medical Research, vol. 131, no. 2, pp. 206–216, 2010. View at Google Scholar · View at Scopus
  104. A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. Van Voorhis, and D. H. Jagasia, “Screening women with polycystic ovary syndrome for metabolic syndrome,” Obstetrics and Gynecology, vol. 106, no. 1, pp. 131–137, 2005. View at Google Scholar · View at Scopus
  105. E. Standl, “Aetiology and consequences of the metabolic syndrome,” European Heart Journal, Supplement, vol. 7, supplement D, pp. D10–D13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Handelsman, “Metabolic syndrome pathophysiology and clinical presentation,” Toxicologic Pathology, vol. 37, no. 1, pp. 18–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. L. G. Kraemer-Aguiar, C. M. Laflor, and E. Bouskela, “Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome,” Metabolism, vol. 57, no. 12, pp. 1740–1746, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. D. G. Harrison, “Cellular and molecular mechanisms of endothelial cell dysfunction,” Journal of Clinical Investigation, vol. 100, no. 9, pp. 2153–2157, 1997. View at Google Scholar · View at Scopus
  110. S. M. Grundy, “Obesity, metabolic syndrome, and cardiovascular disease,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2595–2600, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Aljada, P. Mohanty, H. Ghanim et al., “Increase in intranuclear nuclear factor κB and decrease in inhibitor κB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect,” The American Journal of Clinical Nutrition, vol. 79, no. 4, pp. 682–690, 2004. View at Google Scholar · View at Scopus
  112. P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg, “Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation,” Circulation, vol. 111, no. 11, pp. 1448–1454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. E. Charmandari, C. Tsigos, and G. Chrousos, “Endocrinology of the stress response,” Annual Review of Physiology, vol. 67, pp. 259–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. C.-N. Wang, R. S. McLeod, Z. Yao, and D. N. Brindley, “Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 9, pp. 1481–1491, 1995. View at Google Scholar · View at Scopus
  115. D. Argaud, Q. Zhang, W. Pan, S. Maitra, S. J. Pilkis, and A. J. Lange, “Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5′-flanking sequence,” Diabetes, vol. 45, no. 11, pp. 1563–1571, 1996. View at Google Scholar · View at Scopus
  116. H. Hauner, G. Entenmann, M. Wabitsch et al., “Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium,” Journal of Clinical Investigation, vol. 84, no. 5, pp. 1663–1670, 1989. View at Google Scholar · View at Scopus
  117. C. Grunfeld and D. S. Jones, “Glucocorticoid-induced insulin resistance in vitro: inhibition of insulin-stimulated methylaminoisobutyric acid uptake,” Hormone and Metabolic Research, vol. 18, no. 3, pp. 149–152, 1986. View at Google Scholar · View at Scopus
  118. C. Guillaume-Gentil, F. Assimacopoulos-Jeannet, and B. Jeanrenaud, “Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats,” Diabetologia, vol. 36, no. 10, pp. 899–906, 1993. View at Google Scholar · View at Scopus
  119. R. Andrew, C. R. Gale, B. R. Walker, J. R. Seckl, and C. N. Martyn, “Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort,” Experimental and Clinical Endocrinology and Diabetes, vol. 110, no. 6, pp. 284–290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. G. P. Chrousos, “Stress and disorders of the stress system,” Nature Reviews Endocrinology, vol. 5, no. 7, pp. 374–381, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. N. D. Wong, “Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction,” Preventive Cardiology, vol. 8, no. 1, pp. 47–54, 2005. View at Google Scholar · View at Scopus
  122. D. Deen, “Metabolic syndrome: time for action,” The American Family Physician, vol. 69, no. 12, pp. 2875–2887, 2004. View at Google Scholar · View at Scopus
  123. “National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002.
  124. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  125. “American Diabetes Association. Clinical practice recommendations 2005,” Diabetes Care, vol. 28, supplement 1, pp. S1–79, 2005.
  126. “Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. National Institutes of Health,” Obesity Research, vol. 6, supplement 2, pp. 51S–209S, 1998.
  127. S. Bellentani, R. D. Grave, A. Suppini et al., “Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach,” Hepatology, vol. 47, no. 2, pp. 746–754, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. K. A. Donato, “Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults,” Archives of Internal Medicine, vol. 158, no. 17, pp. 1855–1867, 1998. View at Publisher · View at Google Scholar · View at Scopus
  129. G. E. Duncan, M. G. Perri, D. W. Theriaque, A. D. Hutson, R. H. Eckel, and P. W. Stacpoole, “Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults,” Diabetes Care, vol. 26, no. 3, pp. 557–562, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. L. F. Van Gaal, M. A. Wauters, and I. H. De Leeuw, “The beneficial effects of modest weight loss on cardiovascular risk factors,” International Journal of Obesity, vol. 21, supplement 1, pp. S5–S9, 1997. View at Google Scholar · View at Scopus
  131. P. K. Whelton, L. J. Appel, M. A. Espeland et al., “Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group,” Journal of the American Medical Association, vol. 279, no. 11, pp. 839–846, 1998. View at Publisher · View at Google Scholar · View at Scopus
  132. R. R. Wing, R. Koeske, L. H. Epstein, M. P. Nowalk, W. Gooding, and D. Becker, “Long-term effects of modest weight loss in type II diabetic patients,” Archives of Internal Medicine, vol. 147, no. 10, pp. 1749–1753, 1987. View at Google Scholar · View at Scopus
  133. R. Ross, I. Janssen, J. Dawson et al., “Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial,” Obesity Research, vol. 12, no. 5, pp. 789–798, 2004. View at Google Scholar · View at Scopus
  134. J. O. Hill and H. R. Wyatt, “Role of physical activity in preventing and treating obesity,” Journal of Applied Physiology, vol. 99, no. 2, pp. 765–770, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. D. W. Haslam and W. P. T. James, “Obesity,” The Lancet, vol. 366, no. 9492, pp. 1197–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Toumilheto, J. Lindstrom, J. G. Eriksson et al., “Prevention of type 2 diabetes mellitus with lifestyle intervention or metformin,” The New England Journal of Medicine, vol. 344, no. 18, pp. 1343–1350, 2001. View at Publisher · View at Google Scholar
  137. W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” The New England Journal of Medicine, vol. 346, no. 6, pp. 393–403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. A. Tortosa, M. Bes-Rastrollo, A. Sanchez-Villegas, F. J. Basterra-Gortari, J. M. Nũnez-Cordoba, and M. A. Martinez-Gonzalez, “Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort,” Diabetes Care, vol. 30, no. 11, pp. 2957–2959, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. L. Landaeta-Diaz, J. M. Fernandez, M. Da Silva-Grigoletto et al., “Mediterranean diet, moderate-to-high intensity training, and health-related quality of life in adults with metabolic syndrome,” European Journal of Preventive Cardiology, vol. 20, no. 4, pp. 555–564, 2013. View at Publisher · View at Google Scholar
  140. K. Paletas, E. Athanasiadou, M. Sarigianni et al., “The protective role of the mediterranean diet on the prevalence of metabolic syndrome in a population of greek obese subjects,” Journal of the American College of Nutrition, vol. 29, no. 1, pp. 41–45, 2010. View at Google Scholar · View at Scopus
  141. N. Babio, M. Bulló, J. Basora et al., “Adherence to the Mediterranean diet and risk of metabolic syndrome and its components,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 8, pp. 563–570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. L. F. Lien, A. J. Brown, J. D. Ard et al., “Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome,” Hypertension, vol. 50, no. 4, pp. 609–616, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Garg, J. P. Bantle, R. R. Henry et al., “Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus,” Journal of the American Medical Association, vol. 271, no. 18, pp. 1421–1428, 1994. View at Publisher · View at Google Scholar · View at Scopus
  144. W. E. Mitch, “Beneficial responses to modified diets in treating patients with chronic kidney disease,” Kidney International, Supplement, vol. 67, no. 94, pp. S133–S135, 2005. View at Google Scholar · View at Scopus
  145. A. N. Fabricatore, “Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference?” Journal of the American Dietetic Association, vol. 107, no. 1, pp. 92–99, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. R. R. Wing, R. W. Jeffery, L. R. Burton, C. Thorson, K. S. Nissinoff, and J. E. Baxter, “Food provision vs structured meal plans in the behavioral treatment of obesity,” International Journal of Obesity, vol. 20, no. 1, pp. 56–62, 1996. View at Google Scholar · View at Scopus
  147. T. A. Wadden, M. L. Butryn, and K. J. Byrne, “Efficacy of lifestyle modification for long-term weight control,” Obesity Research, vol. 12, no. S12, pp. 151S–162S, 2004. View at Google Scholar · View at Scopus
  148. A. G. Johnson, T. V. Nguyen, and D. Davis, “Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects,” Journal of Hypertension, vol. 19, no. 6, pp. 1053–1060, 2001. View at Publisher · View at Google Scholar · View at Scopus
  149. J. He, L. G. Ogden, S. Vupputuri, L. A. Bazzano, C. Loria, and P. K. Whelton, “Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults,” Journal of the American Medical Association, vol. 282, no. 21, pp. 2027–2034, 1999. View at Publisher · View at Google Scholar · View at Scopus
  150. J. He, L. G. Ogden, L. A. Bazzano, S. Vupputuri, C. Loria, and P. K. Whelton, “Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first national health and nutrition examination survey epidemiologic follow-up study,” Archives of Internal Medicine, vol. 162, no. 14, pp. 1619–1624, 2002. View at Publisher · View at Google Scholar · View at Scopus
  151. L. J. Appel, M. W. Brands, S. R. Daniels, N. Karanja, P. J. Elmer, and F. M. Sacks, “Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association,” Hypertension, vol. 47, no. 2, pp. 296–308, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. P. K. Whelton, J. He, J. A. Cutler et al., “Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials,” Journal of the American Medical Association, vol. 277, no. 20, pp. 1624–1632, 1997. View at Google Scholar · View at Scopus
  153. American Diabetes Association, “Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications,” Diabetes Care, vol. 25, no. 1, pp. 202–212, 2002. View at Publisher · View at Google Scholar
  154. D. J. A. Jenkins, C. W. C. Kendall, L. S. A. Augustin et al., “Glycemic index: overview of implications in health and disease,” The American Journal of Clinical Nutrition, vol. 76, no. 1, pp. 266S–273S, 2002. View at Google Scholar · View at Scopus
  155. N. M. McKeown, J. B. Meigs, S. Liu, E. Saltzman, P. W. F. Wilson, and P. F. Jacques, “Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort,” Diabetes Care, vol. 27, no. 2, pp. 538–546, 2004. View at Publisher · View at Google Scholar · View at Scopus
  156. P. D. Thompson, D. Buchner, I. L. Piña et al., “Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity),” Circulation, vol. 107, no. 24, pp. 3109–3116, 2003. View at Publisher · View at Google Scholar · View at Scopus
  157. S. M. Grundy, B. Hansen, S. C. Smith Jr., J. I. Cleeman, and R. A. Kahn, “American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management,” Circulation, vol. 109, no. 4, pp. 551–556, 2004. View at Publisher · View at Google Scholar · View at Scopus
  158. M. L. Pollock, B. A. Franklin, G. J. Balady et al., “Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association,” Circulation, vol. 101, no. 7, pp. 828–833, 2000. View at Google Scholar · View at Scopus
  159. The Diabetes Prevention Program Research Group, “The Diabetes Prevention Program (DPP): description of lifestyle intervention,” Diabetes Care, vol. 25, no. 12, pp. 2165–2171, 2002. View at Publisher · View at Google Scholar
  160. W. L. Haskell, I.-M. Lee, R. R. Pate et al., “Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association,” Circulation, vol. 116, no. 9, pp. 1081–1093, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. B. H. Goodpaster, J. He, S. Watkins, and D. E. Kelley, “Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, pp. 5755–5761, 2001. View at Publisher · View at Google Scholar · View at Scopus
  162. C. A. Slentz, B. D. Duscha, J. L. Johnson et al., “Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE—a randomized controlled study,” Archives of Internal Medicine, vol. 164, no. 1, pp. 31–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  163. R. R. Pate, M. Pratt, S. N. Blair et al., “Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine,” Journal of the American Medical Association, vol. 273, no. 5, pp. 402–407, 1995. View at Google Scholar · View at Scopus
  164. E. S. Ford, H. W. Kohl III, A. H. Mokdad, and U. A. Ajani, “Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults,” Obesity Research, vol. 13, no. 3, pp. 608–614, 2005. View at Google Scholar · View at Scopus
  165. J. P. Koplan and W. H. Dietz, “Caloric imbalance and public health policy,” Journal of the American Medical Association, vol. 282, no. 16, pp. 1579–1581, 1999. View at Publisher · View at Google Scholar · View at Scopus
  166. R. R. Wing, “Behavioral weight control,” in Handbook of Obesity Treatment, T. A. Wadden and A. J. Stunkard, Eds., pp. 301–316, Guildford Press, New York, NY, USA, 2002. View at Google Scholar
  167. T. A. Wadden, B. G. McGuckin, R. A. Rothman, and S. L. Sargent, “Lifestyle modification in the management of obesity,” Journal of Gastrointestinal Surgery, vol. 7, no. 4, pp. 452–463, 2003. View at Publisher · View at Google Scholar · View at Scopus
  168. C. K. B. Ferrari, “Functional foods and physical activities in health promotion of aging people,” Maturitas, vol. 58, no. 4, pp. 327–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  169. P. W. F. Wilson and S. M. Grundy, “The metabolic syndrome practical guide to origins and treatment: part I,” Circulation, vol. 108, no. 12, pp. 1422–1424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  170. G. J. Krejs, “Metabolic benefits associated with sibutramine therapy,” International Journal of Obesity, vol. 26, supplement 4, pp. S34–S37, 2002. View at Publisher · View at Google Scholar · View at Scopus
  171. J. M. Miles, L. Leiter, P. Hollander et al., “Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin,” Diabetes Care, vol. 25, no. 7, pp. 1123–1128, 2002. View at Publisher · View at Google Scholar · View at Scopus
  172. C. K. Haddock, W. S. C. Poston, P. L. Dill, J. P. Foreyt, and M. Ericsson, “Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials,” International Journal of Obesity, vol. 26, no. 2, pp. 262–273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  173. S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004. View at Publisher · View at Google Scholar · View at Scopus
  174. F. Folli, A. E. Pontiroli, and W. H. Schwesinger, “Metabolic aspects of bariatric surgery,” Medical Clinics of North America, vol. 91, no. 3, pp. 393–414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  175. L. Sjöström, A.-K. Lindroos, M. Peltonen et al., “Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery,” The New England Journal of Medicine, vol. 351, no. 26, pp. 2683–2693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  176. B. M. Wolfe and J. M. Morton, “Weighing in on bariatric surgery: procedure use, readmission rates, and mortality,” Journal of the American Medical Association, vol. 294, no. 15, pp. 1960–1963, 2005. View at Publisher · View at Google Scholar · View at Scopus
  177. R. G. Bakker-Arkema, M. H. Davidson, R. J. Goldstein et al., “Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia,” Journal of the American Medical Association, vol. 275, no. 2, pp. 128–133, 1996. View at Publisher · View at Google Scholar · View at Scopus
  178. J. R. Downs, M. Clearfield, S. Weis et al., “Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study,” Journal of the American Medical Association, vol. 279, no. 20, pp. 1615–1622, 1998. View at Publisher · View at Google Scholar · View at Scopus
  179. J. Davignon, “Beneficial cardiovascular pleiotropic effects of statins,” Circulation, vol. 109, no. 23, pp. III39–III43, 2004. View at Google Scholar · View at Scopus
  180. Z. T. Bloomgarden, “Obesity, hypertension, and insulin resistance,” Diabetes Care, vol. 25, no. 11, pp. 2088–2097, 2002. View at Google Scholar · View at Scopus
  181. P. C. Deedwania, D. B. Hunninghake, H. E. Bays, P. H. Jones, V. A. Cain, and J. W. Blasetto, “Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome,” The American Journal of Cardiology, vol. 95, no. 3, pp. 360–366, 2005. View at Publisher · View at Google Scholar · View at Scopus
  182. M. L. Kashyap, M. E. McGovern, K. Berra et al., “Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia,” The American Journal of Cardiology, vol. 89, no. 6, pp. 672–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  183. J. M. Morgan, D. M. Capuzzi, R. I. Baksh et al., “Effects of extended-release Niacin on lipoprotein subclass distribution,” The American Journal of Cardiology, vol. 91, no. 12, pp. 1432–1436, 2003. View at Publisher · View at Google Scholar · View at Scopus
  184. D. B. Hunninghake, M. E. McGovern, M. Koren et al., “A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin,” Clinical Cardiology, vol. 26, no. 3, pp. 112–118, 2003. View at Google Scholar · View at Scopus
  185. E. Mills, J. Prousky, G. Raskin et al., “The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTNI8054903],” BMC Clinical Pharmacology, vol. 3, article 4, 2003. View at Publisher · View at Google Scholar · View at Scopus
  186. S. M. Grundy, G. L. Vega, M. E. McGovern et al., “Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial,” Archives of Internal Medicine, vol. 162, no. 14, pp. 1568–1576, 2002. View at Publisher · View at Google Scholar · View at Scopus
  187. D. A. Leaf, W. E. Connor, D. R. Illingworth, S. P. Bacon, and G. Sexton, “The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study,” Journal of the American Medical Association, vol. 262, no. 22, pp. 3154–3160, 1989. View at Publisher · View at Google Scholar · View at Scopus
  188. G. Steiner, “Fibrates in the metabolic syndrome and in the diabetes,” Endocrinology and Metabolism Clinics of North America, vol. 33, no. 3, pp. 545–556, 2004. View at Publisher · View at Google Scholar
  189. D. Streja, “Combination therapy for the treatment of dyslipidemia,” Current Opinion in Investigational Drugs, vol. 5, no. 3, pp. 306–312, 2004. View at Google Scholar · View at Scopus
  190. G. L. Vega, P. T. S. Ma, N. B. Cater et al., “Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome,” The American Journal of Cardiology, vol. 91, no. 8, pp. 956–960, 2003. View at Publisher · View at Google Scholar · View at Scopus
  191. A. S. Wierzbicki, D. P. Mikhailidis, R. Wray et al., “Statin-fibrate combination therapy for hyperlipidaemia: a review,” Current Medical Research and Opinion, vol. 19, no. 3, pp. 155–168, 2003. View at Publisher · View at Google Scholar · View at Scopus
  192. S. D. Turley and J. M. Dietschy, “The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level,” Preventive Cardiology, vol. 6, no. 1, pp. 29–64, 2003. View at Google Scholar · View at Scopus
  193. C. A. Dujovne, M. P. Ettinger, J. F. McNeer et al., “Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia,” The American Journal of Cardiology, vol. 90, no. 10, pp. 1092–1097, 2002. View at Publisher · View at Google Scholar · View at Scopus
  194. D. P. Mikhailidis, G. C. Sibbring, C. M. Ballantyne, G. M. Davies, and A. L. Catapano, “Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy,” Current Medical Research and Opinion, vol. 23, no. 8, pp. 2009–2026, 2007. View at Publisher · View at Google Scholar · View at Scopus
  195. “The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering,” Journal of the American Medical Association, vol. 251, no. 3, pp. 365–374, 1984. View at Publisher · View at Google Scholar
  196. S. Engeli, J. Böhnke, K. Gorzelniak et al., “Weight loss and the renin-angiotensin-aldosterone system,” Hypertension, vol. 45, no. 3, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  197. P. K. Whelton, J. He, L. J. Appel et al., “Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program,” Journal of the American Medical Association, vol. 288, no. 15, pp. 1882–1888, 2002. View at Google Scholar · View at Scopus
  198. Z. H. Israili, B. Lyoussi, R. Hernández-Hernández, and M. Velasco, “Metabolic syndrome: treatment of hypertensive patients,” The American Journal of Therapeutics, vol. 14, no. 4, pp. 386–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  199. S. G. Ball and W. B. White, “Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers—a gap in evidence-based medicine,” The American Journal of Cardiology, vol. 91, no. 10, pp. 15G–21G, 2003. View at Publisher · View at Google Scholar · View at Scopus
  200. A. H. Barnett, S. C. Bain, P. Bouter et al., “Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 351, no. 19, pp. 1952–1961, 2004. View at Publisher · View at Google Scholar · View at Scopus
  201. H. Abuissa, P. G. Jones, S. P. Marso, and J. H. O'Keefe Jr., “Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials,” Journal of the American College of Cardiology, vol. 46, no. 5, pp. 821–826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  202. J. Bosch, S. Yusuf, H. C. Gerstein et al., “Effect of ramipril on the incidence of diabetes,” The New England Journal of Medicine, vol. 355, no. 15, pp. 1551–1562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  203. G. Mancia, G. Grassi, and A. Zanchetti, “New-onset diabetes and antihypertensive drugs,” Journal of Hypertension, vol. 24, no. 1, pp. 3–10, 2006. View at Google Scholar · View at Scopus
  204. R. C. Pasternak, “The ALLHAT lipid lowering trial—less is less,” Journal of the American Medical Association, vol. 288, no. 23, pp. 3042–3044, 2002. View at Publisher · View at Google Scholar · View at Scopus
  205. H. R. Black, B. Davis, J. Barzilay et al., “Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT),” Diabetes Care, vol. 31, no. 2, pp. 353–360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  206. “Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),” Journal of the American Medical Association, vol. 288, no. 23, pp. 2981–2997, 2002.
  207. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  208. W. C. Knowler, R. F. Hamman, S. L. Edelstein et al., “Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program,” Diabetes, vol. 54, no. 4, pp. 1150–1156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  209. J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, “Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial,” The Lancet, vol. 359, no. 9323, pp. 2072–2077, 2002. View at Publisher · View at Google Scholar · View at Scopus
  210. T. J. Orchard, M. Temprosa, R. Goldberg et al., “The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial,” Annals of Internal Medicine, vol. 142, no. 8, pp. 611–619, 2005. View at Google Scholar · View at Scopus
  211. R. Ratner, R. Goldberg, S. Haffner et al., “Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program,” Diabetes Care, vol. 28, no. 4, pp. 888–894, 2005. View at Publisher · View at Google Scholar · View at Scopus
  212. M. E. Molitch, “Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program,” Diabetes Care, vol. 26, no. 4, pp. 977–980, 2003. View at Publisher · View at Google Scholar · View at Scopus
  213. J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, “Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial,” Journal of the American Medical Association, vol. 290, no. 4, pp. 486–494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  214. R. Rajagopalan, S. Iyer, and M. Khan, “Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials,” Current Medical Research and Opinion, vol. 21, no. 1, pp. 163–172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  215. T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  216. B. Schieffer, C. Bünte, J. Witte et al., “Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease,” Journal of the American College of Cardiology, vol. 44, no. 2, pp. 362–368, 2004. View at Publisher · View at Google Scholar · View at Scopus
  217. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  218. T. M. Shields and C. H. Hennekens, “Management of metabolic syndrome: aspirin,” Endocrinology and Metabolism Clinics of North America, vol. 33, no. 3, pp. 577–593, 2004. View at Publisher · View at Google Scholar · View at Scopus
  219. C. H. Hennekens, M. L. Dyken, and V. Fuster, “Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American heart association,” Circulation, vol. 96, no. 8, pp. 2751–2753, 1997. View at Google Scholar · View at Scopus
  220. M. J. Blaha, S. Bansal, R. Rouf, S. H. Golden, R. S. Blumenthal, and A. P. DeFilippis, “A practical “ABCDE” approach to the metabolic syndrome,” Mayo Clinic Proceedings, vol. 83, no. 8, pp. 932–943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. R. S. Eidelman, P. R. Hebert, S. M. Weisman, and C. H. Hennekens, “An update on aspirin in the primary prevention of cardiovascular disease,” Archives of Internal Medicine, vol. 163, no. 17, pp. 2006–2010, 2003. View at Publisher · View at Google Scholar · View at Scopus